2024年12月30日 · Read this story here. No. 8 – COYA 302 immune-modulating therapy shows promise in small early trial. Coya Therapeutics’ investigational therapy COYA 302 was found …

2024年12月19日 · In PARADIGM (NCT05357950), a completed Phase 2b study, PrimeC was tested against a placebo, both taken as two tablets by mouth twice daily for six months, in 68 …

2025年1月24日 · New ALS trial data show nearly 2-year survival benefit with NP001. NP001 (sodium chlorite) was associated with a significant survival benefit among a subset of …

2024年11月20日 · What is ASHA-624? ASHA-624 was designed using Asha’s PRISM platform to “glue” the SARM1 protein, a central regulator of nerve fiber degeneration, into an inactive …

2024年12月27日 · It took us more than three months to share freely that Jeff had been diagnosed with ALS. Because he had a large network of friends and colleagues around the world, we …

2024年12月2日 · The trial, dubbed ANQUR (NCT05633459), is now moving toward a dose range-finding phase, which will test two doses within the range established from the dose-escalation …

2024年10月9日 · The new drug application comes on the heels of combined data from Phase 2a (NCT01281631) and Phase 2b (NCT02794857) clinical trials, in which NP001 slowed disease …

2024年12月23日 · Due to substantial increases in the use of healthcare resources, medical costs in the U.S. for people with amyotrophic lateral sclerosis (ALS) rise significantly as the disease …

2024年11月22日 · The upcoming trial intends to investigate the safety and effectiveness of two foralumab doses in 20 ALS patients. It builds on positive findings from multiple sclerosis (MS) …

2025年1月8日 · The number of people living with amyotrophic lateral sclerosis (ALS) in the U.S. is expected to steadily climb — by more than 10% — over this decade, increasing from an …